Miyamoto T, Morita S, Asakawa H, Koyama T, Dokiya T, Kondo M, Yamashita T, Ohkawa T, Kanehira T
Hosp. Nat'l. Inst. Radio, Sci.
Gan No Rinsho. 1989 Mar;35(4):472-6.
Sixty six patients with an advanced or a relapsed cancer have been treated with a combination of radiation and aclarubicin (ACR). The average irradiation dose was 45 +/- 15 Gy, and the combined total dose of ACR ranged from 130 to 260 mg, depending upon the following differing schedules: 10 mg x 3 or 5/w, 20 mg x 2 or 3/w and 20 mg x 2/d x 2/w. The tumor response attained was 70%, including 30% who achieved a complete response. A high response rate also was observed in rather radioresistant cancerous tumor, such as those of the lung, stomach and esophagus. The adverse effects, such as anorexia, nausea, and so on, were found increase with an increase in the dose of ACR. It thus was concluded that for clinical usefulness, 10 mg of ACR should administered every other day in combination with a definite program of radiotherapy.
66例晚期或复发癌症患者接受了放疗与阿克拉霉素（ACR）联合治疗。平均照射剂量为45±15 Gy，ACR的联合总剂量根据以下不同方案在130至260 mg之间：10 mg×3或5次/周，20 mg×2或3次/周，以及20 mg×2次/天×2周。获得的肿瘤缓解率为70%，其中30%达到完全缓解。在对放疗相当抗拒的癌性肿瘤（如肺癌、胃癌和食管癌）中也观察到了较高的缓解率。发现诸如厌食、恶心等不良反应会随着ACR剂量的增加而增加。因此得出结论，为了临床应用，应每隔一天给予10 mg ACR，并结合明确的放疗方案。
